COMMUNIQUÉS West-GlobeNewswire

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
30/06/2025
FDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene’s NIH-sponsored Expanded Access Program NfL EAP biomarker analyses to be conducted early in the 4 th [...]
Cuprina Provides Update on Research Studies with Three Leading Education Institutes
30/06/2025
SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“ Cuprina ” or “the Company ”), a biomedical and biotechnology company dedicated to the development and commercialization of [...]
Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
30/06/2025
No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1 MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. ( [...]
Heartflow to Showcase Landmark DECIDE Data at SCCT 2025, Advancing AI-Driven Care for Coronary Artery Disease
30/06/2025
DECIDE Registry receives top award as company plans to unveil the next generation plaque technology at SCCT Annual Scientific Meeting MOUNTAIN VIEW, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. , the leader [...]
Catheter Precision, Inc. Forms new Joint Venture Called Kardionav to Exploit patented AI Techniques to Create New VT Software platform
30/06/2025
New AI techniques to add to VT ablation tools FORT MILL, S.C., June 30, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically [...]
Spectral AI Announces Submission to FDA of its DeepView® System
30/06/2025
DALLAS, June 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and [...]
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
30/06/2025
Builds on clearances already received by FDA and EMA China has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc [...]
Protara Therapeutics Announces Addition to the Russell 3000® Index
30/06/2025
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the [...]
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors
30/06/2025
REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers [...]
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
30/06/2025
SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today [...]
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
30/06/2025
SPRING Trial Data Presented at BSG Live’25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 Treatment with Nebokitug Is Well-Tolerated and [...]
Tectonic Therapeutic Joins Russell 3000® Index
30/06/2025
WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and [...]
Tilde Sciences Announces Availability Of VECAMYL™ (Mecamylamine) With Exclusive Distribution Through Optime Care Specialty Pharmacy
30/06/2025
JERSEY CITY, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tilde Sciences LLC (“Tilde”), a U.S.–based biopharmaceutical company dedicated to developing therapies for rare diseases with significant unmet need, today announced [...]
HealthLynked Appoints Andrew Mavliev as Chief Technology and Product Officer to Accelerate Direct-to-Consumer Healthcare Innovation
30/06/2025
NAPLES, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. ( OTCQB: HLYK ), a leader in connected healthcare technology, is pleased to announce the appointment of Andrew Mavliev as its new Chief [...]
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
30/06/2025
TARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual [...]
AB Science fait un point sur la renégociation des modalités de remboursement de ses emprunts avec ses créanciers financiers
30/06/2025
COMMUNIQUE DE PRESSE AB SCIENCE FAIT UN POINT SUR LA RENEGOCIATION DES MODALITES DE REMBOURSEMENT DE SES EMPRUNTS AVEC SES CREANCIERS FINANCIERS UN ACCORD DE PRINCIPE A ETE OBTENU SUR UN DECALAGE DE DEUX ANS DU [...]
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
30/06/2025
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE RENEGOTIATION OF LOAN REPAYMENT TERMS WITH ITS FINANCIAL CREDITORS AGREEMENT IN PRINCIPLE HAS BEEN REACHED ON A TWO-YEAR DEFERRAL OF REPAYMENT OF STATE-GUARANTEED LOANS [...]
Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025
30/06/2025
VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies [...]
Le groupe Affidea choisit b-rayZ comme partenaire d’IA privilégié en imagerie mammaire, marquant ainsi le début d’une collaboration stratégique
30/06/2025
LA HAYE, Pays-Bas, 30 juin 2025 (GLOBE NEWSWIRE) -- Dans une démarche stratégique visant à améliorer les résultats des patientes atteintes d’un cancer du sein, Affidea , l’un des principaux prestataires paneuropéens de [...]

Pages